Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS)’s share price shot up 7.5% during mid-day trading on Friday . The stock traded as high as $2.63 and last traded at $2.58, 422,200 shares changed hands during mid-day trading. An increase of 25% from the average session volume of 337,712 shares. The stock had previously closed at $2.40.
Several brokerages have issued reports on APTO. Roth Capital reaffirmed a “buy” rating on shares of Aptose Biosciences in a report on Thursday, May 23rd. Zacks Investment Research raised shares of Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a report on Monday, May 13th. Finally, HC Wainwright decreased their target price on shares of Aptose Biosciences from $8.50 to $6.00 and set a “buy” rating for the company in a report on Wednesday. Seven research analysts have rated the stock with a buy rating, Aptose Biosciences currently has a consensus rating of “Buy” and an average target price of $5.25.
The company has a current ratio of 11.27, a quick ratio of 5.93 and a debt-to-equity ratio of 0.04. The stock has a fifty day moving average price of $2.60.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Aptose Biosciences by 37.3% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 78,829 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 21,400 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Aptose Biosciences during the first quarter valued at approximately $198,000. Boston Advisors LLC purchased a new position in shares of Aptose Biosciences during the first quarter valued at approximately $36,000. Geode Capital Management LLC purchased a new position in shares of Aptose Biosciences during the fourth quarter valued at approximately $33,000. Finally, Sigma Planning Corp purchased a new position in shares of Aptose Biosciences during the second quarter valued at approximately $572,000. 6.35% of the stock is owned by hedge funds and other institutional investors.
About Aptose Biosciences (NASDAQ:APTO)
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Story: How does equity income fit into an investing strategy?
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.